Osteogenezis İmperfekta Tanılı Bireylerde Teriparatid Tedavisinin Retrospektif Olarak Değerlendirilmesi

Abstract

Osteogenezis imperfekta (Oİ) düşük kemik mineral yoğunluğuna ve artmış kemik frajilitesine yol açan kalıtsal bir hastalıktır. Bu makalede kliniğimizde Oİ tanısı ile takipli, tedavilerinde teriparatid veya zolendronik asit (ZA) kullanılan hastaların retrospektif olarak klinik, laboratuvar parametreleri ve kemik mineral yoğunluklarını değerlendirmeyi amaçladık. Takiplerinde teriparatid ile ZA tedavisi alan toplam 9 hasta değerlendirildi. Teriparatid tedavisi alan hastaların tümünde klinik iyileşme sağlandı, tedavi süresince yeni fraktür saptanmadı. Olguların teriparatid tedavisi ile kemik mineral yoğunluklarının stabil seyrettiği görüldü. Teriparatid tedavisi sırasında olgularda yan etki gelişmedi. ZA tedavisi alan hastalarda kemik mineral yoğunlukları değerlendirildiğinde, lomber alanda kemik mineral yoğunluğunda artış izlendi. Olgularda yeni kırık oluşumu tespit edilmedi. ZA tedavisi uygulanan olgularda da tedavi sırasında yan etki gözlenmedi. ZA, erişkin Oİ olgularında tolere edilebilir yan etki profili ile efektif tedavi seçenekleri arasında yer almaktadır. Osteoanabolik bir ajan olan teriparatid de iyi tolere edilebilen, yan etkileri ve yapılan çalışmalarda gözlemlenen kemik mineral yoğunluğu üzerindeki olumlu etkileri de göz önüne alındığında Oİ vakalarında tercih edilebilir tedavi seçeneği olarak karşımıza çıkmaktadır.

Keywords

• Osteogenezis imperfekta,
• teriparatid
• zolendronik asit
• kemik mineral yoğunluğu

Retrospective Evaluation of Teriparatide Therapy in Individuals with Osteogenesis Imperfecta

Abstract

Osteogenesis imperfecta (OI) is an inherited disorder that causes low mineral density and bone fragility. In this article, we aimed to evaluate the clinical and laboratory parameters and bone mineral density of patients in whom teriparatide or zolendronic acid (ZA) was used in follow-up treatment with the diagnosis of OI in our clinic, retrospectively. During the follow-up, 9 patients who received teriparatide or ZA treatment were evaluated. Clinical improvement was achieved in all patients who received teriparatide treatment, no new fractures were detected during the treatment. It was observed that the bone mineral density of the patients treated with teriparatide treatment remained stable. No adverse events were observed during the treatment in the cases treated with teriparatide. When bone mineral density was evaluated in patients receiving ZA treatment, an increase in bone mineral density was observed in the lumbar area. New fractures were not detected in the cases. No adverse events were observed during the treatment in the cases treated with ZA. ZA is one of the effective treatment options with its tolerable adverse event profile in adult OI cases. Teriparatide, an osteoanabolic agent, appears to be the preferred treatment option in OI cases considering its well tolerated adverse events and positive effects on bone mineral density observed in studies. Further longer term studies involving a larger number of patients are needed to confirm and contrast our findings.

Keywords

• Osteogenesis imperfecta
• teriparatide,
• zolendronic acid,
• bone mineral density

References

1. Referans 1- Glorieux FH. Osteogenesis imperfecta. Best Pract Res Clin Rheumatol 2008; 22 (1): 85 - 100.
2. Referans 2- Marini JC, Forlino A, Bachinger HP, Bishop NJ, Byers PH, Paepe A, Fassier F, Fratzl-Zelman N, Kozloff KM, Krakow D, et al. Osteogenesis imperfecta. Nature Reviews: Disease Primers 2017; 3: 17052.
3. Referans 3- Folkestad L, et al. Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT. J Bone Miner Res. 2012; 27 (6): 1405 – 1412.
4. Referans 4 - Gatti D, et al. The volumetric bone density and cortical thickness in adult patients affected by osteogenesis imperfecta. J Clin Densitom. 2003; 6 (2): 173 – 177.
5. Referans 5- Marini JC. Osteogenesis imperfecta: comprehensive management. Adv Pediatr 1988; 35: 391 - 426.
6. Referans 6- Glosten B. Osteogenesis imperfecta. In: Gambling, DR, Douglas MJ, editors. Obstetric anesthesia and uncommon disorders. Philadelphia, WB Saunders; 1998: 213 -8.
7. Referans 7 - Burnei G, Vlad C, Georgescu I, Gavriliu TS, Dan D. Osteogenesis imperfecta: diagnosis and treatment. J Am Acad Orthop Surg 2008;16 (6): 356 - 66.
8. Referans 8- Michaell A.Huber, DDS.Osteogenesis imperfecta.Oral Radiol Endod 2007; 103: 314 - 20.

9. Referans 9- Hekimsoy Z., Osteogenesis İmperfekta. Turkiye Klinikleri J Endocrin. 2009; 4 (3): 85 – 91.
10. Referans 10 - Cheung MS, Glorieux FH. Osteogenesis imperfecta: update on presentation and management. Rev Endocr Metab Disord. 2008; 9: 153 – 160.
11. Referans 11 - Font RF, Garcia ML, Martinez JMO. Osteochemonecrosis of the Jaws due to Bisphosphonate treatments: Update. Med Oral Patol Oral Cir Bucal 2008; 13: 318 - 24.
12. Referans 12 -Sparidans RW, Twiss IM, Talbot S. Bisphosphonates in bone diseases. Pharm World Sci 1998; 20: 206 – 13.
13. Referans 13 - Pavón de Paz I, Iglesias Bolaños P, Durán Martínez M, Olivar Roldán J, Guijarro De Armas G, Parra García JI. Efectos del tratamiento con ácido zoledrónico en pacientes adultos con osteogénesis imperfecta [Effects of zoledronic acid in adults with osteogenesis imperfecta]. Endocrinol Nutr. 2010 Jun - Jul; 57 (6): 245 - 50.
14. Referans 14 -Forteo R. Teriparatide [rDNA origin] injection. Kobe, Japan: Eli Lilly Japan K.K; 2014.
15. Referans 15- Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.Endocr Rev. 2005; 26: 688 – 703.
16. Referans 16- Dobnig H, Sipos A, Jiang Y, et al. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005; 90: 3970.
17. Referans 17 -Orwoll ES, Shapiro J, Veith S, Wang Y, Lapidus J, Vanek C, Reeder JL, Keaveny TM, Lee DC, Mullins MA, Nagamani SC & Lee B. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. Journal of Clinical Investigation 2014; 124: 491 – 498.
18. Referans 18 - Martin E, Shapiro JR. Osteogenesis Imperfecta: epidemiology and pathophysiology. Curr Osteoporos Rep 2007;5: 91 – 97.
19. Referans 19 - Balkefors V, Mattsson E, Pernow Y, Sääf M. Functioning and quality of life in adults with mild-to-moderate osteogenesis imperfecta. Physiother Res Int 2013; 18: 203 - 211.
20. Referans 20 - Rohrbach M, Giunta C. Recessive osteogenesis imperfecta: clinical, radiological, and molecular findings. Am J Med Genet C Semin Med Genet 2012;160: 175 – 189.
21. Referans 21 -Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf F, Garnero P, Arlot M, Raynal C, Pierre J, Meunier PJ. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res. 2006;21(2): 300 – 306.
22. Referans 22- Shapiro JR, Thompson CB, Wu Y, Nunes M, Gillen C. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. Calcif Tissue Int.2010; 87 (2): 120 – 129.
23. Referans 23- Aslan A, Gülcü A, Özmeriç A. Yaşlı Postmenapozal Osteoporozlu Hastalarda Tedavi Sonuçlarımız: Oral ve Parenteral Bifosfonatların Karşılaştırılması. Turk J Osteoporos 2018; 24: 53 – 8.
24. Referans 24-Land C, Rauch F, Glorieux FH. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res 2006; 21: 374 - 379.
25. Referans 25- Lin JH. Bisphosphonates: a review og their pharmacokinetic properties. Bone 1996; 18: 75 – 85.
26. Referans 26-Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1 - 34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434.
27. Referans 27-Sridharan K, Sivaramakrishnan G. Interventions for Improving Bone Mineral Density and Reducing Fracture Risk in Osteogenesis Imperfecta: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials. Curr Clin Pharmacol. 2018; 13 (3): 190 - 198.
28. Referans 28-Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1 - 34)] are dependent on duration of treatment and dose. Toxicol Pathol. 2004; 32: 426 - 43.
29. Referans 29-Harper KD, Krege JH, Marcus R, Mitlak BH. Osteosarcoma and teriparatide? J Bone Miner Res. 2007; 22: 334.
30. Referans 30- Subbiah V, Madsen VS, Raymond AK, Benjamin RS, Ludwig JA. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int. 2010; 21: 1041 - 1045.